Mahdieh Mojibian, Sedigheh Soheilykhah, Mohammad Ali Fallah Zadeh, Maryam Jannati Moghadam,
Volume 13, Issue 11 (11-2015)
Abstract
Background: Vitamin D supplementation during pregnancy has been supposed to defend against adverse gestational outcomes. Objective: This randomized clinical trial study was conducted to assess the effects of 50,000 IU of vitamin D every two weeks supplementation on the incidence of gestational diabetes (GDM), gestational hypertension, preeclampsia and preterm labor, vitamin D status at term and neonatal outcomes contrasted with pregnant women that received 400 IU vitamin D daily. Materials and Methods: 500 women with gestational age 12-16 weeks and serum 25 hydroxy vitamin D (25 (OH) D ) less than 30 ng/ml randomly categorized in two groups. Group A received 400 IU vitamin D daily and group B 50,000 IU vitamin D every 2 weeks orally until delivery. Maternal and Neonatal outcomes were assessed in two groups. Results: The incidence of GDM in group B was significantly lower than group A (6.7% versus 13.4%) and odds ratio (95% Confidence interval) was 0.46 (0.24-0.87) (P=0.01). The mean ± SD level of 25 (OH) D at the time of delivery in mothers in group B was significantly higher than A (37.9 ± 19.8 versus 27.2 ± 18.8 ng/ml, respectively) (P=0.001). There were no differences in the incidence of preeclampsia, gestational hypertension, preterm labor, and low birth weight between two groups. The mean level of 25 (OH) D in cord blood of group B was significantly higher than group A (37.9 ± 18 versus 29.7 ± 19ng/ml, respectively). Anthropometric measures between neonates were not significantly different. Conclusion: Our study showed 50,000 IU vitamin D every 2 weeks decreased the incidence of GDM.
Sedigheh Soheilykhah, Mahdieh Mojibian, Maryam Jannati Moghadam,
Volume 15, Issue 3 (5-2017)
Abstract
Background: Elevated serum ferritin concentration is associated with insulinresistance and diabetes. Recently it has also been described in gestational diabetesmellitus (GDM).
Objective: A prospective study was done to determine whether there was arelationship between serum ferritin concentration in early pregnancy and the risk ofGDM.
Materials and Methods: A study was performed on 1,384 pregnant women withgestational age of 12-16 weeks. A blood sample was obtained for measurement offerritin in the first trimester. Diagnosis of GDM was done by 75 gr oral glucosetolerance test between 24-28 wk.
Results: Women who developed GDM had a higher concentration of serum ferritinthan women who did not develop GDM (p=0.01). A ferritin concentration of 45ng/ml was calculated to be the 75th percentile for healthy pregnant women.Considering this level 32% in the GDM group and 25.2%of normal subjectsexhibited high ferritin levels (p=0.01). The risk of GDM with these high levels offerritin was 1.4-fold higher than that for subjects with lower concentrations. The Odds Ratio was 1.4 (95% CI= 1-1.87) (p=0.01). After adjusted for age Odds Ratiowas 1.38 (95% CI=1.02-1.86) (p=0.03) and after adjustment for pre-pregnancy BodyMass index, the adjusted odds ratio was 1.31 (CI= 0.96-1.79) (p=0.08). Aftermultivariable adjustment (age and body mass index), the adjusted odds ratio was 1.3(0.95-1.8) (p=0.09).
Conclusion: High serum ferritin can be regarded as a significant risk factor for thedevelopment of gestational diabetes
